SCHEMBL5879770

SCHEMBL5879770

O=C(Cc1cccc(Cl)c1)N/N=C/c1ccccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.65
LMNA P02545 4/20 0.64
KDM4E B2RXH2 4/20 0.57
TDP1 Q9NUW8 2/20 0.57
HTT P42858 2/20 0.57
GAA P10253 2/20 0.57
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
POLB P06746 3/20 0.57
NPC1 O15118 2/20 0.57
THRB P10828 1/20 0.56
CNR2 P34972 1/20 0.56
NCOA1 Q15788 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NCOA3 Q9Y6Q9 1/20 0.56
MAPT P10636 2/20 0.56
RAB9A P51151 1/20 0.56
CASP3 P42574 1/20 0.56
CTRC Q99895 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879773 1.00 KDM1A (0.65) KDM1ALMNAKDM4ETDP1HTT
SCHEMBL13628735 0.81 LMNA (0.76) LMNAKDM4ETDP1HTTGAA
SCHEMBL14066163 0.79 POLB (0.60) LMNAKDM4ETDP1HTTGAA
SCHEMBL13628750 0.79 LMNA (0.67) LMNAKDM4ETDP1HTTMEN1
SCHEMBL684939 0.79 KDM1A (1.00) KDM1ALMNAKDM4ETDP1HTT
SCHEMBL14066142 0.78 SGK1 (0.85) LMNAKDM4ETDP1MEN1KMT2A
SCHEMBL13628751 0.78 LMNA (0.63) LMNAKDM4ETDP1HTTGAA
SCHEMBL1669896 0.78 MEN1 (0.63) LMNAKDM4EHTTMEN1KMT2A
SCHEMBL1669892 0.78 MEN1 (0.63) LMNAKDM4EHTTMEN1KMT2A
SCHEMBL13628696 0.77 SGK1 (0.71) LMNAKDM4ETDP1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 KDM1A 1196/4885LMNA 4281/4885KDM4E 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.